Europe - FRA:56S1 - FR0013154002 - Common Stock
The current stock price of 56S1.DE is 211.4 EUR. In the past month the price increased by 21.6%. In the past year, price increased by 33.29%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TN8.DE | THERMO FISHER SCIENTIFIC INC | 25.16 | 182.80B | ||
| DAP.DE | DANAHER CORP | 28.28 | 134.07B | ||
| LO3.DE | LONZA GROUP AG-REG | 37.36 | 43.89B | ||
| QTS.DE | IQVIA HOLDINGS INC | 18.99 | 31.81B | ||
| DIM.PA | SARTORIUS STEDIM BIOTECH | 59.74 | 20.35B | ||
| SRT3.DE | SARTORIUS AG-VORZUG | 51.82 | 17.69B | ||
| SRT.DE | SARTORIUS AG | 42.17 | 14.40B | ||
| ILU.DE | ILLUMINA INC | 24.03 | 13.18B | ||
| ESF0.DE | EUROFINS SCIENTIFIC | 17.53 | 11.49B | ||
| ERF.PA | EUROFINS SCIENTIFIC | 16.91 | 11.09B | ||
| QIA.DE | QIAGEN N.V. | 20.44 | 8.95B | ||
| 1BRKR.MI | BRUKER CORP | 16.34 | 5.00B |
Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The company is headquartered in Aubagne, Paca and currently employs 10,134 full-time employees. The firm covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The firm operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.
SARTORIUS STEDIM BIOTECH
Zone Industrielle les Paluds Avenue de Jouques, Bp 1051, Aubagne Cedex
Aubagne PACA FR
Employees: 10134
Phone: 33442845600
Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The company is headquartered in Aubagne, Paca and currently employs 10,134 full-time employees. The firm covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The firm operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.
The current stock price of 56S1.DE is 211.4 EUR. The price decreased by -0.09% in the last trading session.
SARTORIUS STEDIM BIOTECH (56S1.DE) has a dividend yield of 0.33%. The yearly dividend amount is currently 0.71.
56S1.DE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
SARTORIUS STEDIM BIOTECH (56S1.DE) operates in the Health Care sector and the Life Sciences Tools & Services industry.
The PE ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 60.4. This is based on the reported non-GAAP earnings per share of 3.5 and the current share price of 211.4 EUR.
The Revenue of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 9.03% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ChartMill assigns a technical rating of 10 / 10 to 56S1.DE. When comparing the yearly performance of all stocks, 56S1.DE is one of the better performing stocks in the market, outperforming 87.51% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE. Both the profitability and the financial health of 56S1.DE get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months 56S1.DE reported a non-GAAP Earnings per Share(EPS) of 3.5. The EPS decreased by -16.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.96% | ||
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| Debt/Equity | 0.5 |
18 analysts have analysed 56S1.DE and the average price target is 239.46 EUR. This implies a price increase of 13.27% is expected in the next year compared to the current price of 211.4.
For the next year, analysts expect an EPS growth of 27.61% and a revenue growth 9.03% for 56S1.DE